DEF: Annexon, Inc. Announces 2025 Annual Meeting of Stockholders

Annexon, Inc. will hold its 2025 Annual Meeting of Stockholders virtually on June 5, 2025, to elect directors, ratify the selection of KPMG LLP as the independent accounting firm, and approve executive compensation.

Summary

• Annexon, Inc. is holding its 2025 Annual Meeting of Stockholders on June 5, 2025, at 8:00 a.m. Pacific Time, via live audio webcast.
• The meeting will address the election of two Class II directors, ratification of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, and a non-binding advisory vote on executive compensation.
• The record date for the Annual Meeting is April 8, 2025, with 109,714,404 shares of common stock outstanding and entitled to vote.
• Stockholders can vote online, by phone, or by mail, and can submit questions in advance or during the meeting.
• The Board of Directors recommends voting 'For' the election of directors, the ratification of KPMG LLP, and the approval of executive compensation.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, indicating a neutral to slightly positive outlook due to the Board's recommendations and the company's commitment to corporate governance and diversity.

Positives

• The company is providing a virtual meeting option to facilitate stockholder attendance and participation.
• The Board is recommending 'For' votes on all proposals, indicating confidence in the company's direction.
• The company has a diverse workforce, with a significant percentage of female and diverse employees.
• Over 97% of votes cast at last year's annual meeting were in favor of the say-on-pay proposal.

Risks

• The advisory vote on executive compensation is non-binding, meaning the Board is not obligated to act on the outcome.
• The company's success depends on the election of qualified directors and the ratification of a competent independent accounting firm.
• The company is subject to risks associated with cybersecurity, which are overseen by the Audit Committee.

Future Outlook

The Board will continue to periodically review the leadership structure and may make changes in the future as it deems appropriate.

Management Comments

• Douglas Love, President and CEO, cordially invites stockholders to attend the Annual Meeting.
• The Board believes that separating the positions of chair of the Board and Chief Executive Officer allows the CEO to focus on day-to-day operations and strategy, while the chair leads the Board in its oversight role.

Industry Context

The company's focus on transformative medicines for autoimmune and neurodegenerative diseases aligns with broader trends in the biopharmaceutical industry.

Comparison to Industry Standards

• The company's executive compensation program is reviewed by an independent consultant, Alpine Rewards, to ensure competitiveness with industry standards.
• The company's corporate governance practices, such as director independence and committee oversight, are consistent with Nasdaq listing rules and SEC regulations.
• The company's clawback policy aligns with the Dodd-Frank Wall Street Reform and Consumer Protection Act and applicable Nasdaq rules.

Related Party Transactions

• In February 2023, Alerce Medical Technology Partners, L.P., affiliated with director Muneer A. Satter, purchased shares of common stock through an at-the-market offering.
• In December 2023, Alerce Medical Technology Partners, L.P. purchased shares of common stock in a private placement.
• In December 2023, Logos Funds purchased pre-funded warrants, which were later exercised for shares of common stock.
• In June 2024, Redmile Group, LLC purchased pre-funded warrants to purchase up to 7,000,000 shares of common stock.

Stakeholder Impact

• Shareholders are asked to vote on key proposals that will impact the company's governance and direction.
• Employees are affected by the company's compensation policies and diversity initiatives.
• The company's success in developing transformative medicines will impact patients suffering from debilitating diseases.

Next Steps

• Stockholders are encouraged to vote by proxy before the Annual Meeting.
• The company will file a Form 8-K to publish the final voting results after the Annual Meeting.

Key Dates

Keywords

Annual Meeting, Stockholders, Proxy Statement, Board of Directors, KPMG LLP, Executive Compensation, Director Election, Corporate Governance, Annexon